Allogene Therapeutics(US:ALLO)2026-03-12 20:07Financial Performance - Allogene ended Q4 2025 with $258.3 million in cash, cash equivalents, and investments, extending its cash runway into Q1 2028[8]. - Research and development expenses for Q4 2025 were $28.6 million, totaling $150.2 million for the full year, which includes $12.9 million of non-cash stock-based compensation[18]. - General and administrative expenses for Q4 2025 were $13.8 million, totaling $56.8 million for the full year, which includes $24.7 million of non-cash stock-based compensation[18]. - The net loss for Q4 2025 was $38.8 million, or $0.17 per share, with a full-year net loss of $190.9 million, or $0.87 per share[18]. - The company anticipates operating cash expenses of approximately $150 million for 2026, with GAAP operating expenses expected to be around $210 million[14]. Clinical Trials and Research - The pivotal Phase 2 ALPHA3 trial of cema-cel is designed to evaluate whether early, MRD-guided consolidation can prevent recurrence of large B-cell lymphoma (LBCL)[4]. - The interim futility analysis for the ALPHA3 trial is planned for April 2026, comparing MRD clearance rates between cema-cel and observation[6]. - ALLO-329, a dual-targeted CAR T therapy, is currently in the Phase 1 RESOLUTION trial, with proof-of-concept data expected in June 2026[10]. Strategic Initiatives - Allogene is exploring partnering opportunities for ALLO-316, which has shown significant response rates in metastatic solid tumors[11]. - The company aims to deliver allogeneic CAR T therapy at biologic-like scale, enhancing access across both academic and community care settings[19].